Financial Data and Key Metrics Changes - Fourth quarter revenue was $660.5 million, a decrease of 5.2% year-over-year, primarily due to lower pass-through costs in clinical pharmacology and clinical development businesses [21] - Full year 2025 revenue was $2,723.4 million, an increase of 1% year-over-year, driven by higher revenue in clinical pharmacology, partially offset by lower FSP revenue [22] - Adjusted EBITDA for the fourth quarter was $54 million, compared to $56 million in the prior year, while full year adjusted EBITDA was $189.9 million, towards the higher end of guidance [24][25] - Net loss for the fourth quarter was $32.5 million, an improvement from a net loss of $73.9 million in the prior year [25] - Operating cash flow for the fourth quarter was $129.1 million, and free cash flow was $121.6 million, both exceeding expectations [26] Business Line Data and Key Metrics Changes - The clinical pharmacology business saw increased revenue, contributing to the overall revenue growth, while FSP revenue continued to face headwinds [22][24] - The company secured significant new and repeat wins in Q4, including a long-term clinical pharmacology partnership with a top 5 large pharma company [9] Market Data and Key Metrics Changes - The macro environment showed signs of stabilization and early recovery, with funding activity rebounding significantly in the second half of 2025 [7] - Client engagement levels increased, with shorter decision-making timelines and more constructive conversations, particularly in biotech [8] Company Strategy and Development Direction - The company is focused on disciplined execution and positioning itself to benefit from improving market conditions, emphasizing commercial, operational, and financial excellence [8][18] - The strategy includes expanding commercial opportunities through a framework called the three Rs: reach, relevance, and repeat [9][10] - The company is investing in AI and advanced technologies to improve efficiency and quality in clinical research, viewing AI as a force multiplier rather than a replacement for human roles [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the recovery in the biotech sector, noting improved client engagement and decision-making timelines [38] - The company anticipates an uneven recovery in the first half of 2026 but expects to build momentum in the second half as outsourcing trends remain steady [8] Other Important Information - The company paid down approximately $76 million of senior secured notes in Q4, reinforcing its commitment to improving capital structure [21] - The backlog at year-end was $7.7 billion, with a book-to-bill ratio of 1.14 for the quarter and 1.02 for the trailing twelve months [24] Q&A Session Summary Question: Outlook on the overall backdrop, particularly on biotech - Management noted that the cautious optimism reflects improved client engagement and decision-making timelines, with constructive dialogues about the 2026 pipeline [38] Question: Key margin levers and revenue flow-through to the bottom line - Management indicated that revenue growth is crucial for margin improvement, and they expect strong flow-through when revenue increases [42][43] Question: Insights on bookings mix and RFP flow - Management reported a healthy mix of Phase II and Phase III studies, with increased RFP flow from biotech customers [57] Question: AI's impact on customer conversations and outsourcing behavior - Management clarified that while AI is a topic of discussion, it has not materially changed outsourcing behavior, and its role is seen as a productivity tool rather than a replacement [104]
Fortrea (FTRE) - 2025 Q4 - Earnings Call Transcript